Firehawk® Gains CFDA Approval to Extend Shelf Life to Two Years

Shanghai, China - Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently gained approval from China Food and Drug Administration ("CFDA") to extend the shelf life of its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®") to two years.
The revolutionary third-generation drug-eluting stent Firehawk® is the result of eight years of research and development of MicroPort® and is the world's first and only target eluting stent ("TES"). Firehawk® was approved for market launch by the CFDA in 2014, and was approved to add 24 specifications in 2015. With its shelf life further extended, Firehawk® is expected to benefit more Chinese patients with coronary artery diseases.